Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedBeijing Municipality was added to the Locations section, replacing the former 'Beijing Municipality Locations' listing, and the page revision was updated to v3.3.3 with the HHS Vulnerability Disclosure link removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedNotice about potential delays due to government funding has been removed; core trial details, contacts, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedUpdates appear to be minor formatting and wording adjustments across sections. There are no changes to the study design, primary or secondary outcomes, enrollment numbers, or eligibility criteria.SummaryDifference0.4%

- Check91 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about government funding impacts and NIH Clinical Center status; removed the previous v3.1.0 label.SummaryDifference3%

- Check98 days agoChange DetectedUpdate includes new revision tag v3.1.0 and new contact numbers (+86 21 20673222, +86 21 20673203), replacing the old revision tag v3.0.2.SummaryDifference0.1%

Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.